Evidence map›Paper›PMID 40041440›Full record

Trial reportOpen forum infectious diseases2025

New All-Oral Short-term Regimen for Multidrug-Resistant Tuberculosis: A Semi-randomized Controlled Trial Conducted in China.

Wei Jing, Qingfeng Wang, Jun Wang, Liping Ma, Mailing Huang, Jing Wang, Yadong Du, Baoyun Cai, Wenhui Shi, Qi Li and 3 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wei JingDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Qingfeng WangDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Jun WangDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Liping MaDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Mailing HuangDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Jing WangDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Yadong DuDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Baoyun CaiDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Wenhui ShiDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Qi LiDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Xuelian LiDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Naihui ChuDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.
Wenjuan NieDepartment of Tuberculosis, Beijing Chest Hospital of Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to evaluate the efficacy and safety of an all-oral short-term regimen for treating multidrug-resistant tuberculosis (MDR-TB). Methods: In this semirandomized, controlled, multicenter clinical study, patients with MDR-TB who were sensitive to fluoroquinolones were assigned to treatment groups at enrollment. Patients were assigned to group C (4-6 months: bedaquiline + linezolid + clofazimine + moxifloxacin + cycloserine; 5 months: clofazimine + moxifloxacin + cycloserine) unless this protocol was unsuitable or unacceptable, in which case they were randomly assigned to group A (4-6 months: isoniazid + ethambutol + pyrazinamide + protionamide + amikacin + clofazimine + moxifloxacin; 5 months: ethambutol + pyrazinamide + clofazimine + moxifloxacin) or group B (4-6 months: isoniazid + ethambutol + pyrazinamide + protionamide + linezolid + clofazimine + moxifloxacin; 5 months: ethambutol + pyrazinamide + clofazimine + moxifloxacin). The primary outcome was the proportion of patients achieving successful outcomes. Results: From September 2020 to June 2023, 397 patients with MDR-TB were screened and 360 were enrolled. Among them, 90.3% of group C achieved good treatment outcomes, as compared with 57.1% in group A (control) and 75.0% in group B. Group C demonstrated higher sputum culture conversion and pulmonary cavity closure rates than group B, with group A showing the lowest rates. The most common adverse events were skin blackening (29.3%) and hyperuricemia (20.6%). Prolonged QT intervals were observed in 39 participants, predominantly in group C (24.3%). Conclusions: The all-oral 9- to 11-month short-term regimen shows promise as a new treatment option for MDR-TB. Incorporating bedaquiline into an orally administered regimen may improve treatment outcomes and reduce relapse rates. Despite certain limitations, these findings provide valuable insights for developing improved treatments for MDR-TB in China.

Indexed as

bedaquilinemultidrug resistantoutcomesafetytuberculosis

Identifiers

PMID40041440
PMCPMC11878549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.